Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 5/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.37 |
| ▸ | IKZF3 | Q9UKT9 | 4/20 | 0.37 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.36 |
| ▸ | ITK | Q08881 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20046716 | 0.91 | CRBN (0.41) | CRBNESR1ARALDH1A1HPGD | |
| SCHEMBL20046709 | 0.88 | CRBN (0.43) | CRBNESR1ARALDH1A1HPGD | |
| SCHEMBL22692240 | 0.87 | CRBN (0.58) | CRBNESR1ARIKZF3IRAK1 | |
| SCHEMBL20046717 | 0.84 | CRBN (0.54) | CRBNESR1IKZF2IKZF3DDB1 | |
| SCHEMBL20046714 | 0.83 | CRBN (0.54) | CRBNESR1IKZF2IKZF3DDB1 | |
| SCHEMBL25059028 | 0.83 | CRBN (0.56) | CRBNESR1ARIKZF2IKZF3 | |
| SCHEMBL25059030 | 0.79 | CRBN (0.41) | CRBNESR1ARIKZF2IKZF3 | |
| SCHEMBL22661322 | 0.79 | CRBN (0.55) | CRBNESR1ARIKZF3IRAK1 | |
| SCHEMBL22661395 | 0.79 | CRBN (0.55) | CRBNESR1ARIKZF3IRAK1 | |
| SCHEMBL20046406 | 0.79 | CRBN (0.56) | CRBNESR1ARALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844021-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844021-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | CRBN 3/4885ESR1 98/4885AR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.